newsfilter
← Latest News
Business Wire·

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

AgeX Therapeutics , Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the "Deficiency Letter") from